HHS Winds Down mRNA Vaccine Development Efforts Under BARDA

Strategic Insights -

The U.S. Department of Health and Human Services (HHS) has initiated a coordinated wind-down of its mRNA vaccine development efforts under the Biomedical Advanced Research and Development Authority (BARDA). This move involves canceling 22 mRNA vaccine development projects valued at nearly $500 million, as the current vaccines have proven ineffective against upper respiratory infections such as COVID-19 and influenza. HHS Secretary Robert F. Kennedy Jr. explained that this decision came after reviewing scientific data and consulting experts. Funding will be redirected toward safer and more effective vaccine platforms that can maintain efficacy even as viruses evolve.

Key Takeaways:

  • HHS has announced the start of a coordinated wind-down of its mRNA vaccine development efforts under BARDA, effective immediately.
  • The wind-down involves canceling 22 mRNA vaccine development projects valued at nearly $500 million.
  • The current mRNA vaccines have proven ineffective against upper respiratory infections such as COVID-19 and influenza.
  • HHS Secretary Robert F. Kennedy Jr. explained that the decision came after reviewing scientific data and consulting experts.
  • Funding will be redirected toward vaccine platforms that are safer and more effective.
  • BARDA will terminate contracts with institutions like Emory University and Tiba Biotech.
  • Major pharmaceutical companies, including Pfizer, Sanofi Pasteur, and CSL Seqirus, will see their pre-award solicitations canceled.
  • Collaborations with the Department of Defense's Joint Program Executive Office involving vaccine projects with AAHI, AstraZeneca, HDT Bio, and Moderna/UTMB are being restructured.
  • Despite the wind-down, some late-stage contracts such as those with Arcturus and Amplitude will continue to completion.
  • HHS has instructed its partner, Global Health Investment Corporation (GHIC), to halt all equity investments in mRNA technology.

Statistics:

  • 22 mRNA vaccine development projects canceled, total value: $499 million.
  • Current mRNA vaccines ineffective against upper respiratory infections such as COVID-19 and influenza.
  • HHS will redirect funding toward safer and more effective vaccine platforms.
  • 500 million of investments in mRNA technology will be impacted.

Sources:

  • "HHS Winds Down mRNA Vaccine Development Efforts Under BARDA" (2023)
  • Euclid Infotech Pvt. Ltd.
  • Contify.com